Merck KGaA to take on Biogen, Novartis with long-sought EMA nod for MS pill
admin 25th August 2017 Uncategorised 0Six years after regulators in both the U.S. and Europe said they wouldn’t approve Merck KGaA’s oral multiple sclerosis drug, cladribine, the German company has scored an unlikely victory, winning European approval to market it in 28 countries. But competing with more established rivals won’t be easy.
More: Merck KGaA to take on Biogen, Novartis with long-sought EMA nod for MS pill
Source: fierce